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Abstract
Background: Purinoceptors have emerged as mediators of chronic inflammation and neurodegenerative processes.
The ionotropic purinoceptor P2X7 (P2X7R) is known to modulate proinflammatory signaling and integrate neuronal-glial
circuits. Evidence of P2X7R involvement in neurodegeneration, chronic pain, and chronic inflammation suggests that
purinergic signaling plays a major role in microglial activation during neuroinflammation. In this study, we investigated
the effects of methamphetamine (METH) on microglial P2X7R.
Methods: ESdMs were used to evaluate changes in METH-induced P2X7R gene expression via Taqman PCR and protein
expression via western blot analysis. Migration and phagocytosis assays were used to evaluate functional changes in
ESdMs in response to METH treatment. METH-induced proinflammatory cytokine production following siRNA silencing of
P2X7R in ESdMs measured P2X7R-dependent functional changes. In vivo expression of P2X7R and tyrosine hydroxylase
(TH) was visualized in an escalating METH dose mouse model via immunohistochemical analysis.
Results: Stimulation of ESdMs with METH for 48 h significantly increased P2X7R mRNA (*p < 0.0336) and protein
expression (*p < 0.022). Further analysis of P2X7R protein in cellular fractionations revealed increases in membrane
P2X7R (*p < 0.05) but decreased cytoplasmic expression after 48 h METH treatment, suggesting protein mobilization
from the cytoplasm to the membrane which occurs upon microglial stimulation with METH. Forty-eight hour METH
treatment increased microglial migration towards Fractalkine (CX3CL1) compared to control (****p < 0.0001). Migration
toward CX3CL1 was confirmed to be P2X7R-dependent through the use of A 438079, a P2X7R-competitive antagonist,
which reversed the METH effects (****p < 0.0001). Similarly, 48 h METH treatment increased microglial phagocytosis
compared to control (****p < 0.0001), and pretreatment of P2X7R antagonist reduced METH-induced phagocytosis
(****p < 0.0001). Silencing the microglial P2X7R decreased TNF-α (*p < 0.0363) and IL-10 production after 48 h of METH
treatment. Additionally, our studies demonstrate increased P2X7R and decreased TH expression in the striata of
escalating dose METH animal model compared to controls.
Conclusions: This study sheds new light on the functional role of P2X7R in the regulation of microglial effector
functions during substance abuse. Our findings suggest that P2X7R plays an important role in METH-induced microglial
activation responses. P2X7R antagonists may thus constitute a novel target of therapeutic utility in neuroinflammatory
conditions by regulating pathologically activated glial cells in stimulant abuse.
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Background
Microglia, the resident macrophages of the CNS, are
the driving force behind the neuroinflammatory re-
sponse to CNS injury. As the immune sentinels and
first responders, microglia constantly survey the envir-
onment by extending and retracting their processes [1, 2].
Microglial activation, also known as microgliosis, may
occur as a consequence of a single stimulus or multiple
stimuli. During microgliosis, microglia transition from
a surveillant, ramified phenotype to an amoeboid, mo-
tile phenotype with migratory and phagocytic capacities
[1, 3, 4]. Microgliosis is also associated with the gener-
ation of neuroinflammatory mediators and cellular ex-
pansion [1, 3]. Acute microgliosis is transient and is
usually resolved within 1 month after the initial activation
[5, 6]. However, chronic microgliosis is the result of
hyperactive microglia creating a continuous, self-
propagating feedback loop that leads to sustained
neuroinflammation. Sustained inflammation further
promotes the generation and accumulation of neuro-
toxic inflammatory mediators that contribute to neural
damage in neurodegenerative diseases and psychosti-
mulant drug abuse [1, 3].
Although the molecular mechanisms of microglial ac-
tivation remain unknown, the ATP-sensitive P2 purino-
ceptors are implicated as the primary factor in initiating
microgliosis [2]. In particular, the ligand-gated P2X7 re-
ceptor (P2X7R) is known to contribute to inflammatory
responses and is implicated in several neurodegenerative
diseases [2, 7, 8]. P2X7R activation results in the release
of proinflammatory mediators, such as IL-1β, in re-
sponse to injury [2]. The concurrent increases in the ex-
pression of P2X7R and activation of microglia suggest
that P2X7R-induced microglial activation may contrib-
ute to the microglial migration, phagocytosis, and cyto-
kine release during neuroinflammation [2, 8, 9].
Methamphetamine (METH) exposure is known to pro-
mote microglial activation and production of proinflam-
matory cytokines and chemokines [10]. Moreover,
METH-induced microgliosis appears to precede METH-
induced neurotoxicity [11–13]. While the potent effects
of METH are known to initiate and promote neurotox-
icity, the direct effect of METH on microglia is less
understood [14, 15]. Moreover, microgliosis occurs
within minutes and may be sustained for up to several
weeks in vivo [16]. Here, we demonstrate that METH
alters microglial effector functions through P2X7R.
We also demonstrate that chronic exposure of METH
in vivo results in exacerbated microglial P2X7R ex-
pression, indicating a role for this receptor in regulat-
ing immune cell inflammatory responses to METH.
We suggest that P2X7R plays an important role in
the underlying mechanism of METH-induced micro-
glial activation.
Methods
METH administration in vivo
Male C57BL/6 mice 6 weeks of age were purchased from
Jackson Labs, housed in specific pathogen-free condi-
tions, and given unlimited access to food and water. Pro-
tocols for the use of animals were in accordance with
the guidelines of and were approved by the Institutional
Animal Care and Use Committees of Temple University,
which is an American Association for the Accreditation
of Laboratory Animal Care accredited facility.
Methamphetamine hydrochloride was purchased from
Sigma-Aldrich (St. Louis, MO). Mice were weight-
matched and randomly divided into saline or METH
groups. Mice in the METH group were subcutaneously
administered a gradual escalating METH dose twice a
day from 0.675–10 mg/kg over 6 days, with total doses
for each day represented in Fig. 5a. Beginning on day 7,
mice were subcutaneously administered a single dose of
10 mg/kg/day until the mice were sacrificed on day 56.
Cell culture
Embryonic stem cell-derived microglia (ESdM), a gener-
ous gift from Dr. Harald Neumann (University of Bonn
Germany; Bonn, Germany), were cultured in DMEM/
F12 50:50 (Thermo Fisher Scientific; Waltham, MA)
containing N2 supplement (Invitrogen; Waltham, MA)
with 0.048 mM L-glutamine (Thermo Fisher Scientific),
1 % D-glucose (Sigma-Aldrich; St. Louis, MO), and 1 %
penicillin/streptomycin (Thermo Fisher Scientific). The
ESdM are stable proliferating cells with most character-
istics of primary microglia and are a suitable tool to
study microglial function in vitro [17, 18].
Antibodies and reagents
Reagents were purchased from the following sources: meth-
amphetamine hydrochloride (METH) (Sigma-Aldrich);
P2X7R antibody (Alomone; Jerusalem, Israel); tyrosine hy-
droxylase (TH) (Abcam; Cambridge, England); and pHrodo
and Calcein-AM (Life Technologies; Waltham, MA). Poly-
L-lysine (PLL), lipopolysaccharide (LPS), and cytochalasin
D (Cyto D) were purchased from Sigma-Aldrich. Cell via-
bility was determined by LIVE/DEAD assay (Invitrogen)
and showed that METH at 1-1000 μM concentration had
no toxic effects on microglia after 48 h of exposure
(Additional file 1: Figure S1). The concentration of METH
(100 μM) used in the present study is similar to other pub-
lished studies [19, 20]. Optimal concentrations of cytochala-
sin D (5 μM), fractalkine (CX3CL1) (10 ng/mL), LPS
(1 μg/ml), pHrodo (40 μg/ml), and Calcein (5 μM) were de-
termined from dose- and time-dependent response studies.
Immunohistochemistry
Brains of mice administered with escalating non-toxic doses
of METH were harvested, fixed in 4 % paraformaldehyde,
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embedded in paraffin, and sectioned coronally at 5 μm.
Following deparaffinization and dehydration, antigen
retrieval was performed using Citrate Buffer reagent
(Sigma-Aldrich). Sections were blocked with 4 % BSA
and incubated with 1:100 dilution of antibodies specific
for P2X7R (Alomone Labs) and Iba-1 (Wako) or 1:1000
TH (Abcam). Antibodies were detected using Alexa-
fluor conjugates (1:500 for P2X7R and Iba-1 or 1:1500
for TH). DAPI was used for nuclear stain. The immu-
nostained cells were observed using an Eclipse I-80
Microscope (Nikon, Melville, NY) fitted with a
CoolSnap-EZ digital camera (Photometrics, Tucson,
AZ). Image acquisition analysis was performed using
NIS Elements R (Nikon) imaging software.
The expression of TH was quantified on ×20 images
using ImageJ 1.42 software and analyzed based on inte-
grated density, which is the intensity multiplied by the
area of the particles analyzed (http://rsbweb.nih.gov/ij/)
as described [21].
RNA extraction and real-time qPCR
The change in the gene expression profile of the purinergic
receptor P2X7 in ESdM cells was analyzed using real-time
quantitative PCR (qPCR). ESdM cells were seeded at a
density of 2 × 105 cells per well in six-well plates followed
by treatment with 100 μM METH for a time-course from 4
to 72 h (Additional file 2: Figure S2). Total RNA was iso-
lated using the Quick-RNA™ MiniPrep as per manufac-
turer’s instructions (Zymo Research; Irvine, CA). RNA
purity and concentration was determined using a Nano-
Drop ND-1000 spectrophotometer (Thermo Fisher Scien-
tific). Conversion to complementary DNA (cDNA) was
performed by reverse transcription using [1 μg of total
RNA] the High-Capacity cDNA Reverse Transcription kit
(Applied Biosystems; Foster City, CA). Primers were de-
signed for P2X7R forward primer 5′-GAGGTGACGGA-
GAATGTC-3′, P2X7 reverse primer 5′-GCGCCTGGGA
TACTCAG-3′, and P2X7 probe 5′-/56-FAM/ACACTG-
CAGACTACACCTTCCC/36-TAMSp/-3′. cDNA (diluted
1:20) along with forward and reverse primers were mixed
with Taqman Master mix. qPCR was performed on an
Applied Biosystems StepOnePlus Real-Time PCR System
(Applied Biosystems). The PCR conditions consisted of an
initial melting cycle at 95 °C for 15 min, followed by 40 cy-
cles of amplification at 95 °C for 15 s (denaturation), 60 °C
for 30 s (annealing), and 72 °C for 30 s (extension). Raw
data was analyzed using the ΔΔCt method (relative quanti-
fication). Results were expressed in relative gene expression
levels (fold change) compared to the untreated control.
Western blot analysis
To assess the change in protein expression of the recep-
tor P2X7, ESdM cells (500,000 per T75 flask in 10-ml
N2 medium) were incubated with 100 μM METH for
24, 48, and 72 h. IL-1β was used as a positive control.
The cells were washed with PBS before protein was iso-
lated for whole cell lysate using Cell Lytic Reagent and
Protease Phosphatase Inhibitor Cocktail or protein frac-
tionation using mammalian Protein Extraction Kit
(Thermo Fisher Scientific). Cells were lysed per manu-
facturer’s instructions, and protein concentration was
determined using the BCA assay method. Thirty micro-
grams of protein per lane was separated by SDS-gel elec-
trophoresis using 10 % Tris-Glycine gels at 80 V. After
gel electrophoresis, the whole cell lysate, membrane
fraction, and cytoplasmic fraction proteins were trans-
ferred to nitrocellulose membranes overnight at 4 °C.
Membranes with whole cell lysates and cytoplasmic frac-
tions were blocked with 5 % milk before being immuno-
stained overnight for rabbit anti-P2X7R (1:1000,
Alomone; Jerusalem, Israel) or mouse anti-GAPDH
(1:20,000, EMD Millipore MAB374; Darmstadt,
Germany) as loading. Secondary HRP-linked polyclonal
anti-rabbit or anti-mouse antibody (1:2000, Cell Signal-
ing Technology; Danvers, MA) was incubated for 1 h at
room temperature in 5 % milk before developing with
SuperSignal West Femto Chemiluminescent Substrate
(Thermo Fisher Scientific). Membranes with cell mem-
brane fractions were first rinsed briefly in distilled water
and stained with Ponceau S solution (Po-S) (0.5 [w/v] in
1 % [v/v] acetic acid) for 2 min, rinsed in distilled water
to remove excess stain, and imaged using a G:Box
Chemi HR16 (Syngene; Fredrick, MD) gel documenta-
tion system [22]. Protein levels were normalized to
Ponceau-S used as loading control (70–100 kD) [20, 22].
Membranes were then blocked in 5 % milk for 1 h at
room temperature followed by an overnight incubation
with rabbit anti-P2X7R (1:1000, Alomone). Secondary
HRP-linked polyclonal anti-rabbit (1:2000, Cell Signal-
ing) was incubated for 1 h at room temperature in 5 %
milk before developing with SuperSignal West Femto
Chemiluminescent Substrate (Thermo Fisher Scientific).
Membranes were imaged via G:Box Chemi HR16. Band
intensities were measured, and normalized density
values (OD) from the control were plotted.
Phagocytosis assay
To assess phagocytosis, ESdM cells (50,000 cells per T25
flask in 5-ml N2 medium) were incubated with pH-
sensitive pHrodo-conjugated Escherichia coli bioparticles
(Life Technologies). Appropriate flasks were first treated
for 48 h with either METH (100 μM) alone or with 1-h
pretreatment of P2X7R antagonist A 438079 (10 μM).
Cytochalasin D (5 μM) treated for 1 h was used as a
negative control in separate flasks. Briefly, following
treatment, cells were incubated for 1.5 h with pHrodo
green bioparticles (40 μg/ml) at 37 °C in 5 % CO2. Im-
mediately after incubation, cells were rinsed with cold
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phosphate buffered saline, scraped, and washed with
FACS buffer (2 % BSA in PBS) before being re-
suspended in 2 % paraformaldehyde and subjected to
flow cytometric analysis by BD Canto II (BD Biosciences;
Franklin Lake, NJ). Phagocytosis by microglia (FITC+)
was quantified (to 10,000 events), and analysis was car-
ried out using FACS DiVa software (Becton Dickinson)
and FlowJo Software v 8.7 [23].
Migration assay
Quantitative migration assays were carried out using 8-
μm pore FluoroBlock migration plates (Calbiochem;
Darmstadt, Germany) as described previously [23, 24].
ESdM cells were loaded with 5-mM Calcein-AM (Life
Technologies) for 45 min at 37 °C and washed prior to
seeding at 50,000 cells/well in the upper chamber of the
tissue culture insert. CX3CL1 (10 ng/ml) was added to
the lower chamber to stimulate migration. The number
of migrated cells was counted using an inverted fluores-
cence live cell imaging system (Carl Zeiss MicroImaging;
Thornwood, NY). Each experiment was performed in
triplicate, and each experimental well was imaged five
times in different locations, and the results were
expressed as an average of the total number of mi-
grated cells in response to chemoattractant under each
experimental condition. The images were analyzed
with AxioVision version 4.7 software (Carl Zeiss
MicroImaging) and with National Institutes of Health
ImageJ version 1.42 software (http://rsbweb.nih.gov/ij/) as
described [25].
siRNA knockdown of P2X7R
P2X7R expression in ESdM cells was silenced by small
interfering RNA (siRNA) transfection for about 48 h.
P2rx7 Trilencer-27 Mouse siRNA (OriGene Technolo-
gies; Rockville, MD) was used in conjunction with the
jetPRIME transfection reagent (Polypus transfection™;
Bioparc, France) to directly transfect the siRNA in N2
medium according to the transfection protocol. Briefly,
ESdM cells were seeded at a density between 1-2 × 105
in a T25 flask in N2 media. Five nanomolar P2X7R
siRNA or scrambled siRNA was allowed to form du-
plexes with 8-μl jetPRIME transfection reagent in 400-μl
jetPRIME buffer. Cells were transfected and incubated at
37 °C, and 5 % CO2 for 24 h before 2 ml of N2 media
was added to each flask. Cells were incubated for up to
48 h and then tested for other functional readouts. Cells
in medium alone served as controls. P2X7R-specific
siRNA selectively knocked down the target as assessed
by qPCR using GAPDH control.
MSD proinflammatory cytokine panel
To further assess METH-induced changes in micro-
glial function, we analyzed proinflammatory cytokine
production using the Mouse ProInflammatory 7-Plex
Tissue Culture Kit (MSD; Rockville MD) according to
the manufacturer’s instructions. Briefly, P2X7R ex-
pression was silenced by siRNA transfection for about
48 h in ESdM cells, 1.5-2 × 105 per T25 flask, as de-
scribed above. Forty-eight hours after transfection, ap-
propriate flasks were treated for 24, 48, or 72 h with
METH (100 μM). Supernatants were collected, centri-
fuged to remove cellular debris, and concentrated
using the Amicon Ultra-15 Centrifugal Filter Units
(EMD Millipore; Darmstadt, Germany). Twenty-five
microliters of undiluted supernatants was added to
wells of the MSD plate in biological triplicates and in-
cubated for 2 h with vigorous shaking at room
temperature. Detection antibody solution was added
to the wells, followed by further incubation for 1.5 h
with vigorous shaking at room temperature. The plate
was washed three times with PBS+ 0.05 % Tween-20,
and 150 μl of 2X Read Buffer T was added to each
well. Cytokine levels were estimated using provided
standards and calculated by the SECTOR®Imager
2400A and MSD reader software (Meso Scale Discov-
eries, Rockville, MD, USA).
Statistical analysis
Data were compared statistically using the one sample
unpaired t test or a one-way analysis of variance
(ANOVA) followed by post hoc Student Newman Keuls
test to determine which conditions were significantly dif-
ferent from each other, and a Tukey posttest for multiple
comparisons. Results were expressed as mean values
(±SE), with values deemed statistically significant when
p < 0.05.
Results
METH increased gene and protein expression of P2X7R in
microglia
Several animal [26–28] and human studies [15, 29] have
elucidated microglial involvement in METH neurotox-
icity. Building evidence supports the notion that P2X7R
are regulators of neuroinflammatory processes [30] and
are upregulated on microglia [31, 32] in several different
pathologies. To characterize P2X7R expression in the
context of METH-induced microglia activation, we ana-
lyzed the gene and protein expression of P2X7R in the
ESdM [18, 23] cells after 6, 24, 48, and 72 h of METH
treatment (Additional file 2: Figure S2). Changes in the
messenger RNA (mRNA) expression at the 48-h time
point presented the most consistent and significant fold
increase (p < 0.0336) (Fig. 1a).
Our analysis of P2X7R protein from total cell lysate by
western blotting showed increased expression in a time-
dependent manner after METH treatment (Fig. 1b, c).
Interestingly, the P2X7R protein concentration in the
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cytoplasmic fraction (Fig. 1b, c) was reduced in compari-
son to the membrane fraction after METH treatment (48–
72 h). These results are consistent with previously pub-
lished reports that whole cell lysates and membrane frac-
tions of the P2X7R protein (75 kD) also show a proteolytic
product of the P2X7R around 60 kD [33]. These data sug-
gest that not only is the P2X7R protein increased at 48 h
and later time points but there may also be trafficking of
P2X7 from the cytosol to the membrane.
P2X7R antagonist reverses METH-induced microglial
migration
Microglial activation and subsequent migration are im-
portant to maintain CNS homeostasis in response to in-
jury [34]. During the activation process, microglia switch
from a ramified resting state to an amoeboid, motile
phenotype capable of migration [34–36]. To determine
the role of P2X7R in the effects of METH on microglial
migration, ESdM cells were incubated with METH for
48 h and microglial migration was evaluated in response
to the chemokine attractant, CX3CL1 using transwell
migration assay [23] in the absence or presence of
P2X7R competitive antagonist A 438079. As repre-
sented in Fig. 2, microglia migration was significantly
(p < 0.0001) increased following METH treatment. This
increase was significantly attenuated with a 1-h
pretreatment with A 438079 (p < 0.0001) (Fig. 2) sug-
gesting that P2X7R plays an important role in METH-
induced modulation of microglial migration.
Blockade of P2X7R exposure decreases METH-induced
microglial phagocytosis
Microglial activation is characterized by a morphological
change to an amoeboid phenotype capable of phagocytosis
[34–36]. Since purinergic signaling is known to regulate
microglial dynamics [37, 38] and facilitate microglial
phagocytosis, we investigated the possibility that P2X7R
plays a role in altered microglial phagocytic function fol-
lowing METH treatment. Microglial phagocytic activity
was determined by quantifying fluorescence bright green
E. coli bioparticle conjugates by flow cytometry [23]. The
phagocytic activity represents the fold change of the per-
centage of the phagocytic cells in comparison with that of
the control culture. Cells treated with Cyto D (5 μM), an
Fig. 1 METH increases P2X7 purinergic receptor mRNA and protein expression in microglia. a The expression level of P2X7R mRNA in ESdM cells
was modestly increased by treatment with 100 μM METH for 48 h (P < 0.0336). b Representative immunoblots of P2X7R in whole cell lysate,
protein fraction, and Ponceau S staining (Po-S) as loading control. The ratios of P2X7R to protein loading control are shown in the histogram.
Error bars represent mean ± SE of four independent experiments (p < 0.0003). (METH-treated versus control)
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inhibitor of cytoskeletal rearrangement, served as the ex-
perimental negative control. METH-treated microglia
showed a statistically significant increase in phagocytosis
(p < 0.0001) when compared to control. Pretreatment for
1 h with the P2X7R antagonist A 438079 prior to METH
treatment prevented the METH-induced increase in
phagocytosis compared to METH alone (p < 0.0001)
(Fig. 3). These results suggest that P2X7R may play a role
in modulating METH-induced microglial activation.
P2X7R silencing decreases METH-induced microglial
proinflammatory cytokine production
METH-induced microglial activation is known to pro-
mote the release of proinflammatory cytokines, such as
IL-1ß and TNF-α [1, 39, 40]. To evaluate the role of
METH in microglial activation, we analyzed markers of
inflammation subsequent to P2X7R silencing (Fig. 4a).
P2X7R gene expression was silenced for about 48 h con-
tinued with METH treatment for up to 48 h. Evaluation
of proinflammatory cytokines in ESdM cells following
METH treatment for 48 h showed increased production
of TNF-a and IL-10 (data not shown). TNF-α expression
was significantly (p < 0.0363) reduced in cells transfected
with P2X7R siRNA when compared to cells transfected
with scrambled siRNA (Fig. 4b). A similar trend of de-
creased IL-10 expression (Fig. 4b) in METH-treated
ESdM cells was observed in P2X7R siRNA transfected
cells when compared to cells transfected with scrambled
Fig. 2 METH increases migratory capacity of microglia that is P2X7R-dependent. In vitro migration was performed using the transwell migration
assay. ESdM cells (5 × 104) were loaded with 5 mM Calcein-AM. In the lower chamber of the transwell plate, 10 ng/mL of fractalkine (CX3CL1) was
added to determine the number of migrating cells and was visualized under ×40 magnification. a shows representative images of control (a),
10 μM P2X7R-antagonist A 438079 (b), 100 μM METH (c), and 100 μM METH and 10 μM P2X7R-antagonist A 438079 (d) treated ESdM cells. b
Quantification of total cells migrated in response to 100 μM METH and/or A 438079 represents a statistically significant increase in migration towards
CX3CL1 in METH-treated cells as compared to control (****p < 0.0001) that is reversed by pretreatment with A 438079 (****p < 0.0001) (ANOVA)
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siRNA P2X7R, suggesting that P2X7R regulates METH-
induced production of these two cytokines.
Chronic METH decreases tyrosine hydroxylase expression
in vivo
Most recreational METH abusers initially use lower
doses, progressively increasing to higher doses and
eventually engaging in increased amount and frequency
of drug intake [41–43]. In this current study to simulate
a similar pattern, we used an escalating METH dose
schedule for our in vivo mouse experiments to investi-
gate the deleterious effects of METH [41–44]. Male
C57BL/6 mice were subjected to an escalating non-toxic
dose of METH up to 10 mg/kg over a 7-day period
(Fig. 5a), and immunohistochemical analysis of tyrosine
hydroxylase (TH) was performed to evaluate dopamin-
ergic depletion (Fig. 5b) [42, 45, 46]. In accordance
with postmortem evaluation of its expression in
humans and in vivo data from rodents, there was a
dramatic depletion (p < 0.0001) (Fig. 5c) in TH within
the striatum of METH-treated animals in comparison
to control [47–49].
Chronic METH increases P2X7R expression on murine
microglia in vivo
To evaluate the association between the microglial
P2X7R and METH-induced neuroinflammation, immu-
nohistochemistry was performed for markers of puriner-
gic receptor (P2X7R) and reactive microglia (Iba-1). In
the control group, only a few microglia with thin and
long processes were stained positive for P2X7R. How-
ever, a robust increase in Iba-1 immunoreactivity and
hypertrophic cellular morphology of microglia was ob-
served in the METH group that was particularly pro-
nounced in the striatum in comparison to other regions
of the brain. An increase in P2X7R immunoreactivity
was observed in METH-treated mice compared to the
saline group (Fig. 6). P2X7R expression (green) was ob-
served in neurons and was increased concurrent with
Fig. 3 METH increases phagocytic capacity of microglia that is
P2X7-dependent. Graphical representation of microglial phagocytosis
in response to treatment with Cyto D (5 μM), A 438079 (10 μM), METH
(100 μM), or METH (100 μM), and A 438079 (10 μM) was quantified
using flow cytometry. METH (100 μM) significantly increases microglia
phagocytosis (****p < 0.001). Pretreatment with antagonist decreases
phagocytosis as compared to METH-treated cells. (****p < 0.0001)
(ANOVA). Data consist of means ± SEM of three independent
experiments
Fig. 4 METH-induced TNF-α and IL-10 secretion is P2X7R dependent. P2X7R expression was silenced around 80% compared to scrambled siRNA in
ESdM cells (a). Cytokines TNF-α and IL-10 showed trend toward increased expression after treatment with METH (100 μM) (data not shown). Following
P2X7R silencing, there was a significant (*p < 0.0363) decrease in TNF-α in response to METH when compared to scrambled siRNA (b). Evaluation of IL-
10 release showed increased trend with METH treatment followed by a decreased trend with P2X7R silencing, which was not statistically significant (b)
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Iba-1 expression in microglia (Fig. 6). These results are
consistent with reports of increases in P2X7R in patients
suffering from neurodegenerative diseases and neuro-
pathic pain [14]. This suggests that P2X7R may play a
role in modulating METH-induced microglial activation.
Discussion
In this study, we show that (1) METH upregulates
microglia P2X7R mRNA and protein expression, (2)
P2X7R antagonism inhibits METH-induced microglia
migration and phagocytosis, and (3) P2X7R silencing de-
creases METH-induced cytokine production, especially
of TNF-a, suggesting an important role of P2X7R in
METH-induced cytokine regulation. To our knowledge,
the study presented here provides evidence for the first
time that P2X7R plays a role in mediating the effects of
METH on microglia.
METH is a highly addictive psychoactive stimulant
abused worldwide, and it is known to activate microglia
[28]. The long half-life of METH of 12 h and duration
of action contribute to METH abuse, neurotoxic oxida-
tive stress, neuroinflammation, and excitatory neuro-
toxicity [12, 50]. Chronic METH abusers typically use
doses between 5 to 1000 mg within a 24-h period, and
studies suggest that even low, single doses of METH
(0.10–1.00 mg/kg) are capable of inducing significant
release of dopamine from the striatum of rhesus
monkeys [51, 52]. Studies in rodents show that METH-
induced chronic microgliosis precedes damage to
dopaminergic terminals [15]. Furthermore, altered
microglial function induces microglial proliferation
2 days after activation [6, 12, 53, 54].
P2X7R, a member of the P2X subfamily, is an ATP-
sensitive ligand-gated ion channel permeable to cal-
cium, sodium, and potassium ions upon activation [8, 55].
P2X7R is most highly expressed in macrophages/microglia
[55, 56], but it is also expressed in neurons and astrocytes
within the CNS [57–59]. The P2X7R is implicated in
microglial activation; its expression is upregulated in a
variety of neurodegenerative pathologies [2, 8]. Reports
have shown that activation of P2X7 receptors during
CNS pathology initiates the generation and release of
mediators, which may contribute to the progression of
neurotoxic pathologies [60–64]. Thus, P2X7R has been
highlighted as a major contributor to microgliosis,
which may lead to a deleterious cycle of neuroinflamma-
tion and subsequent neurodegeneration [64]. Therefore,
we examined the role of P2X7R in METH-induced micro-
gliosis and aberrant function, in vivo and in vitro by using
stably proliferating ESdM cells that are morphologically
and functionally similar to primary microglia [18, 65–67]
and are an excellent tool to examine the role of purinergic
receptors in microglia [23].
Expression of P2X7R mRNA (Fig. 1a) and protein
(Fig. 1b, c) was increased upon METH treatments. Stud-
ies show that P2X7R expression is posttranscriptionally
controlled in response to varying stimuli [2]. A recent
report demonstrates that posttranslational modification
of P2X7R by palmitic acid on carboxyterminal cysteines
is required for its association with membranous lipid
Fig. 5 METH decreases tyrosine hydroxylase expression in vivo. Mice were subjected to an escalating METH dose schedule (s.c; twice daily) for
6 days, followed by a once daily administration of 10 mg/kg METH up to 56 days (a). Representative images of mouse coronal sections after
56 days are shown (b): Control (n = 3) and METH (n = 3) were stained for tyrosine hydroxylase. Five images at ×20 were taken for each mouse,
and subsequent immunohistochemical analysis and quantification of tissue showed significant decreases (****p < 0.0001) in tyrosine hydroxylase
expression in the striata of mice exposed to chronic METH treatment (c)
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rafts [33]. P2X7R that are not palmitoylated are retained
within the endoplasmic reticulum and are degraded by
proteasomes [33]. Interestingly, in this study, we ob-
served increased expression of P2X7R in the membran-
ous fraction compared to the cytoplasmic fraction in
ESdM exposed to METH (Fig. 1b, c). The significant in-
crease in membranous P2X7R may be in part due to
METH-induced release of the protein from cytoplasmic
vesicular stores, perhaps by increased palmitoylation, in
addition to translation of the increased P2X7R mRNA
[33]. It is also plausible that P2X7R protein shuttles from
the cytoplasm to the membrane subsequent to METH
exposure. The involvement of P2X7R in vesicular traf-
ficking is known [68]. Moreover, vesicular trafficking
regulates the expression of another purinergic recep-
tor isoform, P2X4R, which forms dimers with P2X7R
[68, 69]. Taken together, this data suggests that a simi-
lar mechanism may control the expression of P2X7R.
Activation of P2X7R has been shown to induce micro-
glial migration to the sites of injury and phagocytosis
Fig. 6 METH increases P2X7R expression in murine microglia in vivo. Representative images of immunohistochemical analysis of coronal sections
from control and METH mice are shown: purinergic receptors (green), Iba-1 (red), and DAPI (blue). Images show the presence of P2X7R in neurons
and an increase in P2X7R expression following escalating doses (to 10 mg/kg) of METH in microglia. Yellow arrows point to P2X7R co-staining in
Iba-1-positive microglia, and blue arrows point to neuronal P2X7R staining. To highlight the co-staining, the larger images were taken under ×20
objective magnification (original scale bars, 50 μm) to show Iba-1 (red) and P2X7R (green) without DAPI. The inset images of co-staining in a single
cell were taken under ×40 objective magnification. The small images on the left were taken under ×20 objective magnification (original scale
bars, 50 μm)
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[12, 70]. Consistent with these reports, our studies show
that P2X7R is an important regulator of microglial ef-
fector function in response to stimulant abuse. Engage-
ment of P2X7R activates several secondary messengers
and numerous intracellular signaling cascades down-
stream, thereby controlling trophic behaviors such as ac-
tivation and proliferation [14, 64, 71–73]. In this study,
we show that METH significantly increases microglial
migration toward CX3CL1 compared to untreated con-
trol in a P2X7R-dependent manner (Fig. 2). CX3CL1,
fractalkine, is a chemokine that is produced by neurons
and is integral for maintaining neuron-microglia com-
munication [74]. Extracellular CX3CL1 can influence a
variety of microglial functions under physiological and
pathological conditions, such as microglial synapse
pruning during neuronal plasticity [74–76]. In the CNS,
CX3CL1 acts as a chemoattractant and signals through
the microglial CX3CR1 receptor to facilitate microglial
migration along a concentration gradient [75]. Based on
this phenomenon, we assessed microglial migration
using a CX3CL1 gradient using a previously established
protocol [23]. The increased migration of METH-treated
microglia towards CX3CL1, which was blocked by pre-
treatment of the competitive P2X7R antagonist, is an in-
dicator of METH-induced, P2X7R-dependent microglial
activation (Fig. 2). Similarly, pharmacological inhibition
of P2X7R reversed the METH-induced effect on micro-
glial phagocytosis (Fig. 3).
METH-induced microgliosis involves the release of
proinflammatory cytokines [77]. TNF-α is an important
proinflammatory cytokine that can propagate neuroin-
flammation by initiating the production of other cyto-
kines but may also act in a neuroprotective manner
[77, 78]. In this study, we provide evidence of METH-
induced P2X7R-dependent induction of TNF-α that
may contribute to neuroinflammation (Fig. 4b). Micro-
glial activation also has a role in neuroprotection, and
the secretion of IL-10, an anti-inflammatory cytokine
represents the dual role of this cell type within the
CNS [79].
A goal of this study was to explore the role of puri-
nergic receptors in METH-induced immunomodulatory
responses in vivo. Route of administration [80] in
addition to several other factors [81] determines the
toxic effects of methamphetamine in animal models of
chronic METH exposure. High-dose acute METH ad-
ministration can lead to severe METH toxicity [82],
and a major lethal effect of METH exposure in animal
studies is development of hyperthermia. The escalating
dose paradigm [45] in animal models is known to simu-
late the chronic METH abuser pattern while preventing
the associated physiological consequences [41, 45, 46].
Importantly, evidence suggests that escalating dose
models accurately mimic drug abuse patterns in
humans [42, 45]. The chronic METH models demon-
strate a decrease in dopamine concurrent with
decreases in tyrosine hydroxylase similar to METH-
induced neuropathological changes in humans [83–85].
Previous studies show that tyrosine hydroxylase, the
rate-limiting enzyme in dopamine synthesis, is depleted
with chronic METH administration [86]. Therefore, the
METH-induced reduction of this important enzyme in
dopaminergic neurons can contribute to decreased
dopamine and has been used to estimate dopamine de-
pletion and neuronal loss [48, 49, 76]. Using the escal-
ating METH dose model, we found significant deficits
in tyrosine hydroxylase immunoreactivity (Fig. 5), as re-
ported in other chronic and acute binge models of
METH [83]. The level of tyrosine hydroxylase in the
brain tissue of the escalating METH dose mouse model
was found to be correlated with lower dopamine levels,
as estimated by HPLC in the brain tissue (unpublished
studies). In addition, we show increased P2X7R expres-
sion in neurons as well as expression concurrent with
Iba-1 staining for microgliosis in METH-treated mice
(Fig. 6).
Numerous studies highlight the importance of P2X7R
expression in microglial activation and neuroinflamma-
tion in several brain pathologies including multiple
sclerosis and Alzheimer’s disease [64]. Chronic and
long-term METH abuse damages multiple organ sys-
tems; however, none is more prominent than in the
brain [27, 87]. Immunohistochemistry for reactive
microglia (Iba-1) and P2X7R was particularly pro-
nounced in the striatum of METH-treated animals.
Interestingly, in METH abusers and children with pre-
natal METH exposure, neuroimaging studies demon-
strate abnormalities in brain structure and chemistry,
especially in the striatum [88]. Reactive microgliosis is
observed in animal models of METH exposure and in
the brains of human METH abusers in a process that is
inversely correlated with the duration of METH abstin-
ence [15]. Furthermore, MRS (magnetic resonance
spectroscopy) studies performed in stimulant abuse pa-
tients (including METH and cocaine) to assess brain
metabolites and neurochemicals in selected brain re-
gions show higher concentrations in glia and correlate
well with neuroinflammation [87].
Activation of purinoceptors has been indicated as a
primary factor in microglial response [2]. A number of
neurodegenerative conditions exhibit enhanced P2X7R
expression in the neuroinflammatory foci where the
presence of activated microglia is a concurrent feature
[72, 73, 89, 90].
Conclusions
Our findings in the present work converge in indicating
that purinergic mechanisms contribute to altered
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microglia effector function due to METH. By investigat-
ing the pattern of P2X7R expression in vitro in ESdM
microglia cells and in vivo in mice exposed to an escalat-
ing dose of METH, we show that microglia P2X7 recep-
tors are upregulated in METH-induced microglia
activation. This study sheds new light on the functional
role of P2X7R in the regulation of microglial effector
functions in the setting of substance abuse. P2X7R may
thus play an important role in modulating neuroinflam-
matory responses by regulating pathologically activated
glial cells in stimulant abuse. Antagonists for P2X7R
could have potential therapeutic utility in the regulation
of glial activation in stimulant abuse.
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Additional file 2: Figure S2. The expression level of P2X7R mRNA in
ESdM cells in response to 100 μM METH from 4 to 72 h was quantified
using RT-PCR. (TIF 10526 kb)
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